



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 50618

**Title:** Oncogenic AMAM metallopeptidase domain 28 induces gemcitabine resistance and predicts poor prognosis in pancreatic cancer

**Reviewer’s code:** 05079464

**Reviewer’s country:** Mexico

**Science editor:** Jia-Ping Yan

**Reviewer accepted review:** 2019-07-30 17:20

**Reviewer performed review:** 2019-08-05 17:33

**Review time:** 6 Days

| SCIENTIFIC QUALITY                                     | LANGUAGE QUALITY  | CONCLUSION   | PEER-REVIEWER STATEMENTS                                  |
|--|---|--|---|
| <input type="checkbox"/> Grade A: Excellent            | <input type="checkbox"/> Grade A: Priority publishing                 | <input type="checkbox"/> Accept                    | Peer-Review:  |
| <input checked="" type="checkbox"/> Grade B: Very good | <input checked="" type="checkbox"/> Grade B: Minor language polishing | (High priority)                                    | <input checked="" type="checkbox"/> Anonymous             |
| <input type="checkbox"/> Grade C: Good                 |   | <input type="checkbox"/> Accept                    | <input type="checkbox"/> Onymous                          |
| <input type="checkbox"/> Grade D: Fair                 | <input type="checkbox"/> Grade C: A great deal of language polishing  | (General priority)                                 | Peer-reviewer’s expertise on the topic of the manuscript: |
| <input type="checkbox"/> Grade E: Do not publish       | <input type="checkbox"/> Grade D: Rejection                           | <input type="checkbox"/> Minor revision            | <input type="checkbox"/> Advanced                         |
|  |   | <input checked="" type="checkbox"/> Major revision | <input checked="" type="checkbox"/> General               |
|  |   | <input type="checkbox"/> Rejection                 | <input type="checkbox"/> No expertise                     |
|  |   |  | Conflicts-of-Interest:                                    |
|  |   |  | <input type="checkbox"/> Yes                              |
|  |   |  | <input checked="" type="checkbox"/> No                    |

**SPECIFIC COMMENTS TO AUTHORS**

The discussion made by the authors provides important information about new therapies against to pancreatic cancer, they discuss in appropriately form their results. However, they do not compare their results with other studies in pancreatic cancer cells



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

and other Disintegrin Metalloproteases. I recommend to the authors to review the interaction of the metalloproteases family with other malignant tumors and their therapies. Furthermore, as possible, review the metalloproteases and their interaction in treatment with pancreatic cancer cells, in order to compare the results with other studies. The authors showed the English certificate of the manuscript. However, they send the main text without the suggested corrections by the experts in the language. Thus, I recommend to review this point. The authors presented correct research methods and they provided the approval number of ethics for the study in animals, but they did not presented the ARRIVE guidelines

#### **INITIAL REVIEW OF THE MANUSCRIPT**

##### ***Google Search:***

- The same title
- Duplicate publication
- Plagiarism
- No

##### ***BPG Search:***

- The same title
- Duplicate publication
- Plagiarism
- No



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 50618

**Title:** Oncogenic AMAM metallopeptidase domain 28 induces gemcitabine resistance and predicts poor prognosis in pancreatic cancer

**Reviewer's code:** 03004570

**Reviewer's country:** Turkey

**Science editor:** Jia-Ping Yan

**Reviewer accepted review:** 2019-08-05 09:56

**Reviewer performed review:** 2019-08-09 10:50

**Review time:** 4 Days

| SCIENTIFIC QUALITY                                     | LANGUAGE QUALITY  | CONCLUSION                                 | PEER-REVIEWER STATEMENTS                      |
|--|---|--|---|
| <input type="checkbox"/> Grade A: Excellent            | <input type="checkbox"/> Grade A: Priority publishing       | <input type="checkbox"/> Accept            | Peer-Review:                                  |
| <input checked="" type="checkbox"/> Grade B: Very good | <input checked="" type="checkbox"/> Grade B: Minor language | (High priority)                            | <input checked="" type="checkbox"/> Anonymous |
| <input type="checkbox"/> Grade C: Good                 | polishing   | <input checked="" type="checkbox"/> Accept | <input type="checkbox"/> Onymous              |
| <input type="checkbox"/> Grade D: Fair                 | <input type="checkbox"/> Grade C: A great deal of           | (General priority)                         | Peer-reviewer's expertise on the              |
| <input type="checkbox"/> Grade E: Do not               | language polishing  | <input type="checkbox"/> Minor revision    | topic of the manuscript:                      |
| publish  | <input type="checkbox"/> Grade D: Rejection                 | <input type="checkbox"/> Major revision    | <input type="checkbox"/> Advanced             |
|  |   | <input type="checkbox"/> Rejection         | <input checked="" type="checkbox"/> General   |
|  |   |  | <input type="checkbox"/> No expertise         |
|  |   |  | Conflicts-of-Interest:                        |
|  |   |  | <input type="checkbox"/> Yes                  |
|  |   |  | <input checked="" type="checkbox"/> No        |

**SPECIFIC COMMENTS TO AUTHORS**

This manuscript is a comprehensive basic study that is focused on gemcitabine (GEM) resistance. Authors found that ADAM28 is involved in the GEM resistance and should be a novel target to overcome this resistance. This finding may be clinically important in



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

the future. Materials and methods are adequate. Results are clear. Figures are excellent. There are some small typing errors. First in the line 11 and line 24 of pp#18; the word “expression” is duplicated and one of them should be deleted, and then the word “reveled” should be “revealed”. Secondly, in the line 6 of pp#14, correct sentence should be continued such as “... cancer therapy, in SW1990 cells...”. Similarly, in the line 14 of pp#15, correct sentence should be continued as “....molecules, the correlation between...”. I recommend this article for publication after these minor corrections.

#### **INITIAL REVIEW OF THE MANUSCRIPT**

##### ***Google Search:***

- The same title
- Duplicate publication
- Plagiarism
- No

##### ***BPG Search:***

- The same title
- Duplicate publication
- Plagiarism
- No



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 50618

**Title:** Oncogenic AMAM metallopeptidase domain 28 induces gemcitabine resistance and predicts poor prognosis in pancreatic cancer

**Reviewer's code:** 02734287

**Reviewer's country:** Croatia

**Science editor:** Jia-Ping Yan

**Reviewer accepted review:** 2019-08-06 12:13

**Reviewer performed review:** 2019-08-11 09:11

**Review time:** 4 Days and 20 Hours

| SCIENTIFIC QUALITY                                | LANGUAGE QUALITY                                       | CONCLUSION                                    | PEER-REVIEWER STATEMENTS                      |
|---|--|---|---|
| <input type="checkbox"/> Grade A: Excellent       | <input type="checkbox"/> Grade A: Priority publishing  | <input type="checkbox"/> Accept               | Peer-Review:                                  |
| <input type="checkbox"/> Grade B: Very good       | <input type="checkbox"/> Grade B: Minor language       | (High priority)                               | <input checked="" type="checkbox"/> Anonymous |
| <input type="checkbox"/> Grade C: Good            | polishing  | <input type="checkbox"/> Accept               | <input type="checkbox"/> Onymous              |
| <input checked="" type="checkbox"/> Grade D: Fair | <input type="checkbox"/> Grade C: A great deal of      | (General priority)                            | Peer-reviewer's expertise on the              |
| <input type="checkbox"/> Grade E: Do not          | language polishing                                     | <input type="checkbox"/> Minor revision       | topic of the manuscript:                      |
| publish   | <input checked="" type="checkbox"/> Grade D: Rejection | <input type="checkbox"/> Major revision       | <input type="checkbox"/> Advanced             |
|   |  | <input checked="" type="checkbox"/> Rejection | <input checked="" type="checkbox"/> General   |
|   |  |   | <input type="checkbox"/> No expertise         |
|   |  |   | Conflicts-of-Interest:                        |
|   |  |   | <input type="checkbox"/> Yes                  |
|   |  |   | <input checked="" type="checkbox"/> No        |

**SPECIFIC COMMENTS TO AUTHORS**

Genetic analysis of drug resistant pancreatic cancer is an area if great interest and the results of the study are promising. However, the language of the manuscript is very poor and the paper needs to be completely rewritten in order for the authors to be able



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

to convey their messages and conclusions.

#### INITIAL REVIEW OF THE MANUSCRIPT

##### *Google Search:*

- The same title
- Duplicate publication
- Plagiarism
- No

##### *BPG Search:*

- The same title
- Duplicate publication
- Plagiarism
- No